SK hynix Inc. surpassed industry estimates with its 1.07 trillion won net profit in the third quarter, up 117.5 percent from a year earlier, due to an increase in demand for mobile chips from China's Huawei Technologies Co.
Its third-quarter operating profit more than doubled to 1.29 trillion won from 472.6 billion won last year, while sales jumped 18.9 percent on-year to 8.12 trillion won.
SK hynix, South Korea's second-largest chipmaker, attributed the net profit increase to purchases of its DRAM consumer products by a "certain customer," referring to Huawei, which aggressively purchased semiconductors ahead of the US export restrictions on Sept. 15.
The sharp third-quarter earnings increase was also attributed to a base effect from suffering one of its worst performances last year when its operating profit plummeted 33.2 percent, while sales dropped 5.6 percent.
There was an industry-wide slump during the said period.


Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



